title: [The present and future prospects in rapid molecular diagnosis of tuberculosis and MDR-TB (First Part)].
abstract: Tuberculosis is still one of the diseases with a major medical and social impact, and in terms of early diagnosis (which would imply a fair treatment and established at the time), difficulties related to the delay bacilli isolation in culture, decreased susceptibility testing methods to antituberculosis drugs, lack of methods for differentiation of M. Tuberculosis complex germs of non TB Mycobacteria, may have important clinical implications. Traditional testing of anti-TB drug susceptibility on solid Löwenstein-Jensen medium (gold standard) or liquid media can only be performed using grown samples. Determining the time it takes up to 42 days on solid media and 12 days for liquid media. For MDR/XDR TB cases is absolutely essential to reduce the detection time. In these cases prove their usefulness rapid diagnostic methods. Automatic testing in liquid medium, molecular hybridization methods are currently recommended by the current WHO guidelines. Rapid diagnosis of MDR-TB is extremely useful for the early establishment of an effective treatment tailored more accurately on the spectrum of sensitivity of the resistant strain (thus reducing the risk of developing additional resistance to other drugs) and control the spread of these strains. Genetic diagnostic methods, approved and recommended by the WHO, can reduce the time of diagnosis of TB case and, importantly, the case of MDR TB. They do not replace the current standard diagnostic methods and resistance profile, but complete them in selected cases.
authors.affiliation: Institutul de Pneumologie Marius Nasta, Bucureşti. mihaeleta@yahoo.co.nz
authors.forename: Mihaela
authors.initials: M
authors.lastname: Tănăsescu
authors.forename: Cristian
authors.initials: C
authors.lastname: Didilescu
authors.forename: Constantin
authors.initials: C
authors.lastname: Marica
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D001431:Bacteriological Techniques / Q000379:methods / Q000639:trends; D042241:Early Diagnosis; D054908:Extensively Drug-Resistant Tuberculosis / Q000175:diagnosis; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods / Q000639:trends; D008826:Microbial Sensitivity Tests / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000235:genetics / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction / Q000379:methods; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013997:Time Factors; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents